SCHEMBL5100653

SCHEMBL5100653

OCCOc1cc[c]c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.38
CA1 P00915 2/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
NR1I2 O75469 1/20 0.37
TIPARP Q7Z3E1 1/20 0.35
GAA P10253 2/20 0.35
CYP2D6 P10635 2/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.35
CYP3A4 P08684 1/20 0.34
PDK2 Q15119 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
P2RY12 Q9H244 1/20 0.34
TP53 P04637 1/20 0.34
PRKAB2 O43741 2/20 0.33
PRKAG1 P54619 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5673714 0.81 KMT2A (0.40) ALDH1A1CA1CA12CA9CYP2D6
SCHEMBL6301382 0.80 TIPARP (0.36) TIPARPCYP2D6KMT2APRKAB2PRKAG1
SCHEMBL6306081 0.80 KMT2A (0.43) ALDH1A1RECQLSMN1; SMN2CA1CA12
SCHEMBL9720808 0.79 ALDH1A1 (0.45) ALDH1A1RECQLSMN1; SMN2CA1CA12
SCHEMBL5675616 0.79 TSHR (0.46) SMN1; SMN2KMT2ATP53TSHR
SCHEMBL1225446 0.78 ALDH1A1 (0.44) ALDH1A1RECQLSMN1; SMN2CA1CA12
SCHEMBL16741121 0.78 ALDH1A1 (0.44) ALDH1A1RECQLSMN1; SMN2CA1CA12
SCHEMBL9934560 0.78 ALDH1A1 (0.44) ALDH1A1RECQLSMN1; SMN2CA1CA12
SCHEMBL1009582 0.77 PPARG (0.39) SMN1; SMN2
SCHEMBL1009297 0.77 MAPT (0.54) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452880-B2 Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same F. HOFFMANN-LA ROCHE AG (CH) 2008-11-18 US claimed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US claimed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP claimed
US-20050203091-A1 Heteroaryl-fused pyrazolo derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-15 US claimed
US-7452880-B2 Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same F. HOFFMANN-LA ROCHE AG (CH) 2008-11-18 US disclosed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed
EP-1720878-A1 HETEROARYL-FUSED PYRAZOLO DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-11-15 EP disclosed
US-20050203091-A1 Heteroaryl-fused pyrazolo derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-15 US disclosed
WO-2005085248-A1 HETEROARYL-FUSED PYRAZOLO DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 ALDH1A1 731/4885RECQL 1770/4885SMN1; SMN2 4424/4885
US-20050203091-A1 Heteroaryl-fused pyrazolo derivatives and methods for using the same MAP3K1, MAP3K21, MAP3K2 ALDH1A1 2726/4885RECQL 1255/4885SMN1; SMN2 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.